Key result
Intravenous streptokinase plus aspirin given within six hours of acute ischemic stroke resulted in high mortality and excess brain hemorrhages, prompting premature trial termination.
Why the study?
Does intravenous streptokinase given within six hours of acute ischemic stroke improve outcomes?
Does intravenous streptokinase given within six hours of acute ischemic stroke improve outcomes?
Intravenous streptokinase plus aspirin given within six hours of acute ischemic stroke is associated with unacceptable safety risks, including high mortality and excess brain hemorrhages.
Answers are grounded in this paper and cite their sources.
Avoid streptokinase plus aspirin in acute ischemic stroke; confirms unacceptable risks and redirects research to safer thrombolytics.
The Multicenter Acute Stroke Trial--Italy (MAST-I), a randomized trial of intravenous streptokinase given within six hours of acute ischemic strokes, was stopped prematurely because of high mortality and excess brain hemorrhages in patients randomized to streptokinase plus aspirin. The investigators now report the relation of CT findings to poor outcome--defined as …
No takes yet. Share an insight, caveat, or question.
Louis R. Caplan (1999) studied this question. Intravenous streptokinase plus aspirin given within six hours of acute ischemic stroke resulted in high mortality and excess brain hemorrhages, prompting premature trial termination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: